Abstract
Asthma has reached epidemic proportions with approximately 200 million individuals affected worldwide. The disease is characterized by an oxidant / antioxidant imbalance in the lungs leading to activation of redox-sensitive transcription factors e.g. activator protein 1 (AP-1) and nuclear factor kappa B (NF-kappa B). We have previously described PNRI-299, a small molecule beta-strand mimetic template compound, as an inhibitor of the multifunctional AP endonuclease / redox factor 1 (Ref-1) [1]. PNRI-299 has demonstrable effects on the reduction of AP-1 driven transcription and beneficial pharmacological effects in a mouse asthma model. We now report the synthesis of this molecule and the effects of PNRI-299 on the expression of Leukotriene C4 (LTC4) synthase, a crucial enzyme for the formation of the cysteinyl leukotrienes.
Keywords: ap-1 transcriptional regulation, redox-sensitive transcription factors, activator protein 1
Letters in Drug Design & Discovery
Title: Chemogenomic Investigation of AP-1 Transcriptional Regulation of LTC4 Synthase Expression
Volume: 1 Issue: 3
Author(s): Tiana Chong, Michael McMillan, Jia Ling Teo, William R. Henderson Jr. and Michael Kahn
Affiliation:
Keywords: ap-1 transcriptional regulation, redox-sensitive transcription factors, activator protein 1
Abstract: Asthma has reached epidemic proportions with approximately 200 million individuals affected worldwide. The disease is characterized by an oxidant / antioxidant imbalance in the lungs leading to activation of redox-sensitive transcription factors e.g. activator protein 1 (AP-1) and nuclear factor kappa B (NF-kappa B). We have previously described PNRI-299, a small molecule beta-strand mimetic template compound, as an inhibitor of the multifunctional AP endonuclease / redox factor 1 (Ref-1) [1]. PNRI-299 has demonstrable effects on the reduction of AP-1 driven transcription and beneficial pharmacological effects in a mouse asthma model. We now report the synthesis of this molecule and the effects of PNRI-299 on the expression of Leukotriene C4 (LTC4) synthase, a crucial enzyme for the formation of the cysteinyl leukotrienes.
Export Options
About this article
Cite this article as:
Chong Tiana, McMillan Michael, Teo Ling Jia, Henderson Jr. R. William and Kahn Michael, Chemogenomic Investigation of AP-1 Transcriptional Regulation of LTC4 Synthase Expression, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043398920
DOI https://dx.doi.org/10.2174/1570180043398920 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Role of Leukotriene Receptor Antagonists in Preschool Asthma
Current Respiratory Medicine Reviews Is Ecto-nucleoside Triphosphate Diphosphohydrolase (NTPDase)-based Therapy of Central Nervous System Disorders Possible?
Mini-Reviews in Medicinal Chemistry Current Prospective of Anti-IL-4, -IL-9, and -IL-13 Therapies in Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Implications of Macrolide Therapy in Chronic Sinopulmonary Diseases
Current Pharmaceutical Design Carbon Monoxide - Toxicity of Low-Dose Application
Current Pharmaceutical Biotechnology Oral and Topical Administration of ROQUETTE Schizochytrium sp. Alleviate Skin Inflammation and Improve Wound Healing in Mice
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) CD48 as a Novel Target in Asthma Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The 2010 Patent Landscape for Spleen Tyrosine Kinase Inhibitors+
Recent Patents on Inflammation & Allergy Drug Discovery Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story
Current Pharmaceutical Design Investigation into the Formation Mechanism and Distribution Characteristics of Suspended Microparticles in MQL Grinding
Recent Patents on Mechanical Engineering <i>Lactococcus lactis</i> Administration Modulates IgE and IL-4 Production and Promotes <i>Enterobacteria</i> Growth in the Gut from Ethanol-Intake Mice
Protein & Peptide Letters <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued)